<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article103</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/CANVAS" style="display:block; margin-bottom:10px;">CANVAS Original</a></li>
<h2><strong>CANVAS</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>
<br/>
<br/>
The moderate number of events for vital renal outcomes limits the interpretations about effects on kidney failure.<br/>
Differences in effect sizes could be attributed to trial design or chance since the precision in effect estimates is limited.<br/>
Greater use of other glucose-lowering agents in the placebo group could have underestimated any real benefits and risks.<br/>
Increased rate of amputation with an unknown mechanism necessitates caution in using canagliflozin in patients at risk for amputation.<br/>
The relative risk of amputation varied across subgroups based on history and risk of peripheral vascular disease.<br/>
<h2><strong>FundingSupported by Janssen Research and Development.Further ReadingFull text details available in the New England Journal of Medicine, published on June 12, 2017.</strong></h2>
<p></p>
</div>
</div>
</div>
</div>
</body>
</html>
